Client Assets and Wealth Management - As of December 31, 2024, the Company held client assets under administration of $129.5 billion[11] - The Company had $49.4 billion of client assets under management in fee-based programs[17] - Oppenheimer's Wealth Management division includes 931 financial advisors across 88 offices in the U.S.[11] - Oppenheimer offers a variety of brokerage accounts, including transaction-based pricing and asset-based fee pricing for investment advisory accounts[11] - The company provides comprehensive wealth planning services, including asset management, retirement solutions, and trust services[12] - A portion of Oppenheimer's revenue is derived from commissions from private clients through transaction-based pricing accounts[11] - The firm has seen an increasing number of clients opting for fee-based accounts in recent years[11] - Oppenheimer's services include a range of investment alternatives such as exchange-traded funds, municipal bonds, and mutual funds[11] Investment Banking and Capital Raising - Oppenheimer employs nearly 200 investment banking professionals across the U.S., U.K., and Israel[25] - The investment banking division focuses on sectors including Consumer, Financial Institutions, Healthcare, Industrials, and Technology[26] - Oppenheimer provides a full spectrum of capital raising solutions for corporate clients, including initial public offerings and private placements[28] - Oppenheimer's public finance group assists clients in raising capital for various projects, including local governments and healthcare institutions[44] - The company engages in both corporate and public finance investment banking activities[10] Human Capital and Employee Management - As of December 31, 2024, Oppenheimer employed 3,018 employees, including 931 financial advisors, highlighting the importance of human capital in its operations[63] - The company emphasizes continuous recruitment and retention of financial advisors, which is critical for its growth strategy[69] - Oppenheimer's human capital management strategy is overseen by the Management Committee, ensuring alignment with business needs and industry standards[67] - The company is committed to employee professional development through Oppenheimer University, offering a wide range of training programs[71] - The company has implemented comprehensive healthcare and benefits programs to ensure employee well-being[77] - The ability to attract and retain skilled employees is critical; high turnover and competition for talent may increase recruiting costs and impact business performance[194] - The Company faces competitive pressures from larger firms offering better compensation packages, which may hinder its ability to retain key personnel[195] Regulatory Compliance and Risk Management - Oppenheimer is subject to extensive regulation by the SEC and FINRA, with compliance impacting operational methods and profitability[84] - The company has taken actions to comply with the Sarbanes-Oxley Act, ensuring effective internal control over financial reporting as of December 31, 2024[89] - The implementation of Regulation Best Interest (Reg BI) has resulted in significant structural, technological, and operational changes, with ongoing compliance potentially limiting revenue and increasing costs[92] - The Department of Labor (DOL) proposed a "Retirement Security Rule" package that broadens the fiduciary standard, with compliance expected by September 23, 2024, although implementation is currently stayed[94] - The California Consumer Privacy Act (CCPA) and its amendments have expanded consumer rights regarding personal information, with enforcement beginning on July 1, 2023[95] - Oppenheimer is required to maintain a minimum net capital of at least $1.5 million or 2% of aggregate debit items, whichever is greater, to comply with the Net Capital Rule[104] - As of December 31, 2024, Oppenheimer and its subsidiaries were in compliance with their regulatory capital requirements[106] - The SEC adopted amendments to Regulation S-P, requiring entities to notify individuals of unauthorized access to sensitive customer information within 30 days, effective December 2025[97] - Compliance with the CAT requirements is expected to be expensive and may present potential privacy issues for the company[101] - The Company is subject to extensive securities regulation, and failure to comply could result in monetary penalties or sanctions[160] - New regulations may impose enhanced standards of duty on broker-dealers, potentially limiting the Company's activities[162] - The imposition of penalties for regulatory violations could have a material adverse effect on the Company's operating results and financial condition[165] - The Company faces increased regulatory scrutiny, which has led to a substantial rise in penalties and fines sought by regulatory authorities[166] - Compliance with new regulations, such as "pay-to-play" rules, may adversely affect the profitability of the advisory portion of the Company's business[167] - The implementation of Reg BI may limit revenue and increase compliance costs, including technology and litigation expenses[168] Financial Performance and Market Conditions - The company's operations may be significantly impacted by market fluctuations and global economic conditions, affecting asset values and business flows[116] - The Wealth Management business segment may experience decreased client assets and investor participation during unfavorable market conditions, negatively impacting results[117] - Market volatility and illiquid conditions can complicate the valuation and monetization of financial instruments, potentially leading to significant changes in their values[118] - The Company relies on dividends from its subsidiaries to meet obligations, which may be restricted by regulatory laws[178] - Continued uncertainties in global markets, including geopolitical tensions, could adversely affect the Company's operations and financial condition[184] - The Company's investment banking revenue is highly dependent on transaction volumes, which may decrease in uncertain market conditions, leading to reduced revenue and profitability[186] - A portion of the Company's revenues comes from asset management advisory fees, which are affected by net inflows/outflows and market value changes; poor investment performance could lead to a decline in fee revenue[187] - The Company has faced significant pricing pressure in trading margins and commissions, particularly in fixed income and equity markets, which may impair revenues and profitability[188] - The trend towards passive investing has resulted in a decline in commission revenue from trading transactions, impacting the Company's overall revenue generation[187] Operational and Cybersecurity Risks - Operational risks include potential failures in processes or systems, which could damage the company's reputation and business[134] - The company is exposed to risks from human error and malfeasance, which can lead to material losses[137] - The Company relies heavily on communications and information systems, and any failure or breach could materially affect its financial condition and operations[138] - Cybersecurity incidents among financial services firms are increasing, although the Company has not yet experienced material losses related to such breaches[141] - The Company faces significant costs in maintaining its infrastructure to resist cyberattacks, with senior management regularly briefed on cybersecurity issues[146] Strategic Initiatives and Future Outlook - The Company may pursue strategic acquisitions or joint ventures, but these could lead to unforeseen expenses and operational disruptions[190] - The financial services industry is undergoing rapid technological change, and the Company's future success depends on its ability to adapt to these changes[147] - The Company is evaluating emerging technologies like artificial intelligence and machine learning, which may require significant resources to comply with evolving regulations[150] Shareholder Information - As of December 31, 2024, there were 99,665 shares of Class B Stock outstanding compared to 10,231,736 shares of Class A Stock, limiting the influence of Class A shareholders[175] - The Company declared cash dividends of $0.66 per share in 2024, with future dividends subject to the Board of Directors' discretion[179]

Group 1 - The Value Lab focuses on long-only value investment ideas, targeting international mispriced equities with a portfolio yield of approximately 4% [1][2] - Oppenheimer (NYSE: OPY) is considered attractively valued despite recent price increases, with equity market tailwinds expected to continue into Q4 [2] - The Valkyrie Trading Society consists of analysts sharing high conviction investment ideas that are downside limited and likely to yield non-correlated, outsized returns in the current economic environment [3] Group 2 - The Value Lab offers members real-time portfolio updates, 24/7 chat support, regular global market news reports, feedback on stock ideas, monthly new trades, quarterly earnings write-ups, and daily macro opinions [2]

Core Viewpoint - scPharmaceuticals Inc. is focused on revolutionizing cardiorenal healthcare through patient-centric innovations and will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025 [1]. Company Overview - scPharmaceuticals is dedicated to advancing cardiorenal care with innovative, integrated treatments that address unmet patient needs [3]. - The company aims to be a leading advocate for patient-centric cardiorenal care, promoting global health improvements through specialized, multidisciplinary approaches [4]. - scPharmaceuticals is headquartered in Burlington, MA, and is expanding its reach with integrated therapies and products to improve patient lives [4].

Company Overview - Q32 Bio Inc. is a clinical stage biotechnology company focused on developing biologic therapeutics aimed at restoring immune homeostasis [3] - The company targets potent regulators of the innate and adaptive immune systems to address autoimmune and inflammatory diseases [3] Upcoming Event - Management will participate in a virtual company presentation at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025, at 4:00 p.m. E.T. [1] - A webcast of the presentation will be available on the company's website, with archived replays accessible for 90 days post-event [2] Product Pipeline - Q32 Bio's lead program, bempikibart (ADX-914), is a fully human anti-IL-7Rα antibody currently in a Phase 2 program, aimed at re-regulating adaptive immune function for autoimmune disease treatment [4] - The company also has a program for innate immunity, ADX-097, which is being evaluated in a Phase 2 program and focuses on tissue-targeted regulation of the complement system, differentiating it from current complement therapeutics [4]

Company Overview - Avalo Therapeutics, Inc. is a clinical stage biotechnology company focused on the treatment of immune dysregulation [3] - The company's lead asset is AVTX-009, an anti-IL-1β monoclonal antibody targeting inflammatory diseases [3] - Avalo has two additional drug candidates: quisovalimab (anti-LIGHT monoclonal antibody) and AVTX-008 (BTLA agonist fusion protein) [3] Product Details - AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity [4] - IL-1β is a central driver in the inflammatory process and is implicated in many autoimmune and inflammatory diseases [4] - Evidence suggests that inhibition of IL-1β could be effective in treating hidradenitis suppurativa and various inflammatory diseases in dermatology, gastroenterology, and rheumatology [4] Upcoming Events - Garry A. Neil, M.D., CEO and Chairman of the Board, will present at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025, at 10:00 a.m. ET [1] - A live webcast and replay of the presentation will be available on the Avalo Therapeutics website for at least 30 days [2]

Group 1 - Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing innovative medicines targeting microRNAs [3] - The management team will participate in a fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11th at 2:40 p.m. ET [1] - The live event and replay will be available on the company's investor relations website for 90 days following the presentation [2] Group 2 - Regulus has developed a pipeline supported by a strong intellectual property estate in the microRNA field [3] - The company is headquartered in San Diego, CA [3]

Company Overview - Sensei Biotherapeutics, Inc. is a clinical stage biotechnology company focused on developing next-generation therapeutics for cancer patients [3] - The company utilizes its TMAb™ platform to create conditionally active therapeutics that target the tumor microenvironment [3] Product Development - Sensei's lead product candidate is solnerstotug, an antibody designed to block the VISTA checkpoint selectively in the low pH tumor microenvironment [3] - The mechanism of solnerstotug involves disabling immunosuppressive signals to activate T cells against tumors [3] Upcoming Events - John Celebi, President and CEO of Sensei, will present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference on February 11, 2025, at 10:40 a.m. ET [1] - A webcast of the presentation will be available on the company's website, with a replay accessible for approximately 90 days [2]

Core Points - I-Mab, a U.S.-based global biotech company, focuses on developing precision immuno-oncology agents for cancer treatment [2] - The management team of I-Mab will participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference on February 11-12, 2025 [1] - The conference will include a company presentation and one-on-one meetings, with I-Mab's presentation scheduled for February 11, 2025, from 4:00 to 4:30 PM ET [1] Company Overview - I-Mab is headquartered in Rockville, Maryland, and has operations in Short Hills, New Jersey [2] - The company specializes in precision immuno-oncology, targeting cancer treatment [2] Contact Information - Investor and media inquiries can be directed to PJ Kelleher at LifeSci Advisors [3] - Contact details include a phone number and email for investor relations [3]

Core Viewpoint - Cardiol Therapeutics Inc. is set to present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025, focusing on its clinical-stage anti-inflammatory and anti-fibrotic therapies for heart disease [1]. Company Overview - Cardiol Therapeutics Inc. is a clinical-stage life sciences company specializing in the research and development of therapies targeting inflammation and fibrosis in heart disease [3]. - The company's lead drug candidate, CardiolRx™ (cannabidiol) oral solution, is in clinical development and aims to inhibit the inflammasome pathway, which is crucial in the progression of inflammation and fibrosis related to heart conditions [3]. Clinical Development - Cardiol has received Investigational New Drug Application authorization from the US FDA to conduct clinical studies for CardiolRx™ in recurrent pericarditis and acute myocarditis [4]. - The MAVERIC Program addresses recurrent pericarditis, which can lead to severe symptoms and reduced quality of life, and includes a completed Phase II study and an ongoing Phase III trial [4]. - The ongoing ARCHER trial is a Phase II study focusing on acute myocarditis, a significant cause of heart failure and sudden cardiac death in young adults [4]. Additional Developments - Cardiol is also developing CRD-38, a novel subcutaneous formulation intended for heart failure treatment, which is a leading cause of death and hospitalization, with healthcare costs in the US exceeding $30 billion annually [5].

Exhibit 99.1 Oppenheimer Holdings Inc. Reports Fourth Quarter and Full Year 2024 Earnings New York, January 31, 2025 – Oppenheimer Holdings Inc. (NYSE: OPY) (the "Company" or "Firm") today reported net income of $10.7 million or $1.04 basic earnings per share for the fourth quarter of 2024 compared with net income of $11.1 million or $1.07 basic earnings per share for the fourth quarter of 2023. Fourth quarter and full year 2024 results were significantly impacted by higher pre-tax compensation expenses for ...